A detailed history of Bank Of New York Mellon Corp transactions in Absci Corp stock. As of the latest transaction made, Bank Of New York Mellon Corp holds 224,007 shares of ABSI stock, worth $669,780. This represents 0.0% of its overall portfolio holdings.

Number of Shares
224,007
Previous 285,764 21.61%
Holding current value
$669,780
Previous $880 Million 2.78%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$2.97 - $4.49 $183,418 - $277,288
-61,757 Reduced 21.61%
224,007 $856 Million
Q2 2024

Jul 25, 2024

BUY
$2.92 - $6.58 $700,061 - $1.58 Million
239,747 Added 521.0%
285,764 $880 Million
Q1 2024

Apr 25, 2024

SELL
$3.41 - $5.74 $92,963 - $156,483
-27,262 Reduced 37.2%
46,017 $261 Million
Q4 2023

Jan 29, 2024

BUY
$1.15 - $4.79 $13,143 - $54,744
11,429 Added 18.48%
73,279 $308 Million
Q3 2023

Oct 24, 2023

SELL
$1.28 - $2.41 $1,446 - $2,723
-1,130 Reduced 1.79%
61,850 $81.6 Million
Q2 2023

Aug 03, 2023

SELL
$1.17 - $2.03 $125,390 - $217,557
-107,171 Reduced 62.99%
62,980 $95.7 Million
Q1 2023

May 09, 2023

BUY
$1.58 - $3.41 $268,838 - $580,214
170,151 New
170,151 $298 Million
Q4 2022

Feb 14, 2023

BUY
$2.0 - $3.58 $344,400 - $616,476
172,200 New
172,200 $361,000
Q3 2022

Nov 14, 2022

BUY
$2.95 - $4.83 $142,201 - $232,825
48,204 Added 38.24%
174,245 $546,000
Q2 2022

Aug 15, 2022

SELL
$3.13 - $8.83 $40,007 - $112,865
-12,782 Reduced 9.21%
126,041 $418,000
Q1 2022

May 11, 2022

BUY
$5.87 - $9.46 $644,308 - $1.04 Million
109,763 Added 377.71%
138,823 $1.17 Million
Q4 2021

Feb 11, 2022

BUY
$7.88 - $18.03 $24,301 - $55,604
3,084 Added 11.87%
29,060 $238,000
Q3 2021

Nov 12, 2021

BUY
$10.37 - $30.29 $269,371 - $786,813
25,976 New
25,976 $302,000

Others Institutions Holding ABSI

About Absci Corp


  • Ticker ABSI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 92,843,504
  • Market Cap $278M
  • Description
  • Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process....
More about ABSI
Track This Portfolio

Track Bank Of New York Mellon Corp Portfolio

Follow Bank Of New York Mellon Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.